Enzon Pharmaceuticals Inc.
685 Route 202/206
Bridgewater,
NJ 08807
United States - Map
Phone: 908-541-8600
Fax: 908-575-9457
Web Site: http://www.enzon.com
| Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with cancer and other life-threatening conditions in the United States and internationally. Its products include Oncaspar, a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia; and DepoCyt, an injectable chemotherapeutic agent for the treatment of patients with lymphomatous meningitis. The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; and Adagen, a PEGylated bovine adenosine deaminase enzyme (ADA) used to treat patients afflicted with a type of severe combined immunodeficiency disease, which is caused by the chronic deficiency of ADA. In addition, it licenses its PEGylation platform for products, such as PEG-INTRON, Pegasys, Macugen, and CIMZIA; and provides contract manufacturing services for various injectable products. Enzon is also developing PEG-SN38 for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkins lymphoma; and HIF-1 alpha antagonist for the treatment of cancers and common solid tumors. Further, it offers Recombinant Human Mannose-Binding Lectin, a protein therapeutic to prevent and treat severe infections in individuals with low levels of MBL; and provides contract manufacturing services for various injectable products. The company has development and commercialization agreements with Santaris Pharma A/S; Schering-Plough; Sanofi-Aventis; Medac; Micromet; NatImmune A/S; Nektar; Pacira; and Cephalon France SAS. It markets its therapeutic products through its sales force that includes specialists in oncology, hematology, infectious disease, and various critical care disciplines. The company was founded in 1981 and is based in Bridgewater, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Jeffrey H. Buchalter , 51
Chief Exec. Officer, Pres, Director and Chairman of Exec. Committee |
N/A
| N/A | Mr. Craig A. Tooman , 43
Chief Financial Officer and Exec. VP of Fin. |
N/A
| N/A | Mr. Ralph Del Campo , 57
Exec. VP of Technical Operations |
N/A
| N/A | Dr. Ivan D. Horak M.D., 57
Chief Scientific Officer and Exec. VP of R&D |
N/A
| N/A | Mr. Paul S. Davit , 54
Exec. VP of HR and Corp. Sec. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.36% Nasdaq 
Profile
